ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
This is to inform that AstraZeneca Pharma India Limited had vide its letter dated August 16, 2018 informed the receipt of marketing authorization for Olaparib (Lynparza) 100mg and 150mg tablets which was also indicated for treatment of patient with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.21-05-2024